Full Text View
Tabular View
Study Results
Related Studies
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
This study has been completed.
Study NCT00375219   Information provided by Teva Pharmaceutical Industries

First Received on September 8, 2006.   Last Updated on May 5, 2014   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial